Compare Moderna, Inc. (MRNA) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Williams Companies Inc — how do they compare? Moderna, Inc. trades at $208.24 (market cap $78.65B), while Williams Companies Inc trades at $73.06 (market cap $88.48B). The key difference: Moderna, Inc. and Williams Companies Inc are close in size by market cap, and Williams Companies Inc pays a 2.9% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Williams Companies Inc for 58 Days on average.
| MRNA | WMB | |
|---|---|---|
Market Cap | $78.65B | $88.48B |
Volume | 37,373,437 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $203.46 | $79.40 |
52-Week Low | $22.36 | $56.51 |
Typical Hold Time | 59 Days | 58 Days |
Enterprise Value | $74.80B | $119.11B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Williams Companies (WMB) trades at $71.46, down 1.28% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with 25.18% net income margin and 24.02% ROE, though recent earnings have been mixed with two misses and one beat. Analyst consensus is strongly bullish with 79% buy ratings and an $87.27 price target, representing 22% upside. Recent news highlights WMB's positioning to benefit from AI-driven natural gas demand growth.
WMB offers compelling value with strong cash flow generation and dividend growth potential, though investors face risks from energy market volatility and high debt levels. The company's fee-based revenue model provides stability, while strategic acquisitions like Momentum Midstream enhance growth prospects. Current valuation at 28.82 P/E appears reasonable given the growth trajectory and defensive characteristics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
